Hovione announces key patent grants for its large dose DPI
![](/46/pdcnewsitem/08/19/05/hovione-announces-key-patent-grants-for-its-large-dose-DPI-CPhI%20NL%20week%206.jpg)
Hovione Technology's TwinMax DPI.
TwinMax enabes delivery of doses up to 100 mg formulated as drug alone or engineered particles.
Hovione Technology has announced the notice of patent grants in key territories for one of its large dose dry powder inhaler (DPI) platforms, the TwinMax DPI.
“We achieved unchallenged patent grants for TwinMax in the US, Europe, Japan, China and other territories. Our patented TwinMax will enable pharmaceutical partners to license them and to develop and take forward to the market new drugs requiring delivery of large lung doses", said Peter Villax, Hovione Technology’s CEO.
TwinMax is an innovative, 2-puff, disposable DPI designed for indications requiring high dose delivery to the lungs. It features a patent-granted design enabling delivery of doses up to 100 mg formulated as drug alone or engineered particles.
“The patient simply needs to perform one use step and the large target dose is delivered from 2 puffs to make delivery comfortable. We have designed an enhanced inhaler engine for large dose delivery, while keeping the overall usability of TwinCaps, the world’s leading disposable inhaler with an experience of 10 years treating patients in Japan”, said Dr João Ventura Fernandes, Hovione Technology’s Director of Technology Development and Licensing.
Hovione Technology’s TwinMax and 8Shot dry powder inhalers are designed to enable safe and effective delivery of large doses to the lung. Featuring patented inhaler technology, TwinMax and 8Shot are compatible with drug doses up to 100 mg and 400 mg respectively, delivered conveniently to patients from multiple inhalations. Our Large Dose DPIs are suitable for inhaled delivery of antibiotics, peptides, anti-virals, vaccines, pain or rescue treatments.
![Hovione FarmaCiencia SA](https://www.cphi-online.com/HovioneLogo_Red_small-comp247501.png)
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance